AlzeCure Pharma (ALZCUR) — Cash Flow-to-Debt Ratio
AlzeCure Pharma (ALZCUR) has a Cash Flow-to-Debt Ratio of -0.48x as of September 2025, meaning its operating cash flow of Skr-7.62 Million could theoretically repay 0% of its total liabilities (Skr15.93 Million) in one year. See AlzeCure Pharma (ALZCUR) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
AlzeCure Pharma Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for AlzeCure Pharma across 8 annual periods. Also explore ALZCUR net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for AlzeCure Pharma (2017–2024)
Year-by-year debt coverage analysis for AlzeCure Pharma. For market capitalisation and broader financial context, see AlzeCure Pharma stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.26x | Skr-35.12 Million | Skr8.25 Million | ▼ -1245.7% |
| 2023 | 0.37x | Skr3.06 Million | Skr8.23 Million | ▲ +103.9% |
| 2022 | -9.65x | Skr-99.91 Million | Skr10.35 Million | ▼ -73.1% |
| 2021 | -5.57x | Skr-70.64 Million | Skr12.67 Million | ▲ +43.3% |
| 2020 | -9.83x | Skr-69.51 Million | Skr7.07 Million | ▲ +7.2% |
| 2019 | -10.59x | Skr-50.28 Million | Skr4.75 Million | ▼ -34.7% |
| 2018 | -7.86x | Skr-36.27 Million | Skr4.61 Million | ▼ -287.1% |
| 2017 | -2.03x | Skr-8.42 Million | Skr4.15 Million | — |